| Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis BD Hunter, D Hoda, A Nguyen, L Gouw, B Huber, RR Jensen, J Preedit, ... Experimental Hematology & Oncology 11 (1), 10, 2022 | 9 | 2022 |
| Managing toxicities associated with immune checkpoint inhibitors JJ Park, S Arafath, ST Kumar, R Sharma, D Dixit Journal of the American Academy of Physician Assistants 34 (6), 32-39, 2021 | 7 | 2021 |
| Effect of standardized infliximab dose rounding on an outpatient infusion center JJ Park, L Boutillier, JE Cruz, GE Joung, J Nemeth Journal of managed care & specialty pharmacy 24 (10), 1028-1033, 2018 | 7 | 2018 |
| Pharmacological prevention and management of skeletal-related events and bone loss in individuals with cancer JJ Park, C Wong Seminars in Oncology Nursing 38 (2), 151276, 2022 | 6 | 2022 |
| Challenges and Opportunities in Antimicrobial Stewardship among Hematopoietic Stem Cell Transplant and Oncology Patients A Majumdar, MR Shah, JJ Park, N Narayanan, KS Kaye, PJ Bhatt Antibiotics 12 (3), 592, 2023 | 2 | 2023 |
| Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches YH Shin, X Tian, JJ Park, GY Kim, E Aboujaoude, MG Sturgill Journal of Oncology Pharmacy Practice 28 (1), 159-174, 2022 | 2 | 2022 |
| The Impact of Prior Salvage Treatment With Immune Checkpoint Inhibitors on Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single … JJ Park, J Lin, E Huang, DG Schaar Clinical Lymphoma Myeloma and Leukemia 21 (9), e726-e730, 2021 | 1 | 2021 |
| The FDA accelerated approval program: a double‐edged sword JJ Park HOPA News 18 (4), 3, 2021 | 1 | 2021 |
| Indication withdrawals of small molecule inhibitors from the accelerated approval program JJ Park, D Awad HOPA News 20 (3), 3-7, 2023 | | 2023 |
| Management of Acyclovir-Resistant Herpes Simplex Virus Infection in Patients Undergoing Hematopoietic Stem-Cell Transplantation JJ Park, E Huang, C Ciccosanti Journal of Hematology Oncology Pharmacy 11 (4), 210-215, 2021 | | 2021 |
| Pomalidomide desensitization for hypersensitivity: A case report JJ Park, E Huang, CA Monteleone, MP Kane, DL Cooper Journal of Oncology Pharmacy Practice 26 (5), 1244-1247, 2020 | | 2020 |
| Nivolumab (Opdivo, Bristol-Myers Squibb Co.)—all entries and PAPs S LG | | |
